918博天堂(中华区)官方网站

Huaota is pleased to announce that FDA has approved recently the HB0017 project submitted by the company for clinical trials for treatment of psoriasis. The project was independently developed by Huaota and has global patents.

HB0017 is a humanized monoclonal antibody targeting interleukin-17A (IL-17A and IL-17A/F) and is being developed for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. IL-17 is an important pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various autoimmune diseases and is one of the important therapeutic targets for these diseases.